title: Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective.
abstract: The deep-sea habitat is a source of very potent marine-derived agents that may inhibit the growth of human cancer cells "in vitro" and "in vivo". Salinosporamide-A, Marizomib, by Salinispora species is a proteasome inhibitor with promising anticancer activity (Phase I/II trials). Different deep-sea-derived drugs are under preclinical evaluation. Cancer is a complex disease that may be represented by network medicine. A simple consequence is the change of the concept of target entity from a single protein to a whole molecular pathway and or cellular network. Deep-sea-derived drugs fit well to this new concept.
authors.affiliation: Laboratory of Molecular Epidemiology, IRCCS "San Raffaele Pisana", Via di Val Cannuta, 247-249, Rome, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Russo
authors.affiliation: Laboratory of Molecular Epidemiology, IRCCS "San Raffaele Pisana", Via di Val Cannuta, 247-249, Rome, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Del Bufalo
authors.affiliation: Scientific Direction IRCCS "San Raffaele Pisana"; Via di Val Cannuta, 247-249, Rome, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Fini
keywords: cancer; clinical studies; deep-sea-derived drugs; network; preclinical studies; systems medicine; therapy